Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems [0.03%]
亚洲骨髓纤维化患者的临床表型、突变特征及评分系统的异同分析
Yu-Sung Chang,Yu-Hung Wang,Chao-Hung Wei et al.
Yu-Sung Chang et al.
Various prognostic scoring systems in myelofibrosis (MF) have been developed to guide clinical decision-making in MF. However, discrepancies between different scoring systems for individual patients remain poorly understood, which can resul...
Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow-Up of a Multicenter, Retrospective Real-World Experience With 321 Cases Outside of Controlled Clinical Trials [0.03%]
艾罗珠单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤：321例非临床试验的真实世界经验的延长随访的更正
Published Erratum
Hematological oncology. 2025 Jan;43(1):e70039. DOI:10.1002/hon.70039 2025
Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1-Positive and -Negative Myeloproliferative Neoplasms [0.03%]
近期转化和治疗进展对BCR::ABL1阳性及阴性髓系肿瘤临床病程的影响
Tariq I Mughal,John Mascarenhas,Raajit K Rampal et al.
Tariq I Mughal et al.
Despite the study of BCR::ABL1-positive and -negative myeloproliferative neoplasms (MPNs) providing seminal insights into cancer biology, tumor evolution and precision oncology over the past half century, significant challenges remain. MPNs...
Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma [0.03%]
克唑替尼治疗间变性淋巴瘤激酶阳性淋巴瘤期间成功妊娠病例报告
Veronica Guglielmana,Francesco Maria Fusi,Valentina Giardini et al.
Veronica Guglielmana et al.
Anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma (ALCL) typically affects young individuals and, despite high responsiveness to cytotoxic drugs, relapses occur in over 50% of patients. Crizotinib has improved outcom...
Case Reports
Hematological oncology. 2025 Jan;43(1):e70038. DOI:10.1002/hon.70038 2025
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience [0.03%]
阿卡拉布替尼治疗高风险初治慢性淋巴细胞白血病患者的意大利多中心真实世界回顾性观察研究经验
Idanna Innocenti,Annamaria Tomasso,Diana Giannarelli et al.
Idanna Innocenti et al.
MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia [0.03%]
多发性骨髓瘤、髓外病变和浆细胞白血病的骨髓血浆外泌体 microRNA 谱分析
Jana Gregorova,Monika Vlachova,Petra Vychytilova-Faltejskova et al.
Jana Gregorova et al.
Multiple myeloma is a plasma cell malignancy characterized by an abnormal increase in monoclonal immunoglobulins. Despite significant advances in treatment, some patients progress to more aggressive forms of multiple myeloma, including extr...
Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single-Center Experience of 114 Patients [0.03%]
POEMS综合征骨溶性病变的临床意义——114例单中心回顾分析
Tatsuzo Mishina,Chikako Ohwada,Tomoki Suichi et al.
Tatsuzo Mishina et al.
POEMS syndrome is a multisystemic disease associated with monoclonal plasma cell disorders. Although the presence of bone lesions is included in the diagnostic criteria, their precise manifestations remain unknown. Here, we retrospectively ...
The Role of 24-Month Progression-Free Survival (PFS24) in the Long-Term Evaluation of Patients With Diffuse Large B Cell Lymphoma (DLBCL): A Real-World Single Center Study [0.03%]
评估弥漫性大B细胞淋巴瘤患者长期疗效的24个月无进展生存（PFS24）的价值：一项真实世界单中心研究
Pinelopi Vryttia,Anthi Bouchla,Christina Apostolopoulou et al.
Pinelopi Vryttia et al.
Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real-World Data [0.03%]
基于20年的真实世界数据分析的套细胞淋巴瘤终身治疗轨迹模型
Minna Harmanen,Mika Hujo,Reijo Sund et al.
Minna Harmanen et al.
Mantle cell lymphoma is a rare type of B-cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from tradit...
Childhood ALL and Asparaginase Intensification: Are We at the Brink? [0.03%]
儿童急性淋巴细胞白血病（ALL）与天冬酰胺酶强化治疗：我们是否即将突破？
Shyam Srinivasan
Shyam Srinivasan